ストックスクリーナーアプリを入手
13.38
0.38%
0.05
アフターアワーズ：
13.37
-0.01
-0.07%
前日終値:
$13.33
開ける：
$13.33
24時間の取引高:
1.56M
Relative Volume:
0.90
時価総額：
$42.42B
収益：
$30.27B
当期純損益:
$1.93B
株価収益率:
30.14
EPS:
0.444
ネットキャッシュフロー:
$3.45B
1週間 パフォーマンス:
-1.76%
1か月 パフォーマンス:
-5.31%
6か月 パフォーマンス:
+2.45%
1年 パフォーマンス:
-4.43%
1日の値動き範囲:
$13.30
$13.42
1週間の範囲:
$13.21
$13.64
52週間の値動き範囲:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
TAK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TAK | 13.38 | 42.42B | 30.27B | 1.93B | 3.45B | 0.444 |
| ZTS | 176.96 | 79.84B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.65 | 43.63B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.37 | 15.96B | 15.05B | -883.30M | 1.89B | 1.53 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily
Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily
Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily
Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News
North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Checking in on Takeda Pharmaceutical Co ADR (TAK) after recent insiders movement - Knox Daily
AHH stock rated a Buy by Stifel - Knox Daily
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
Ratios in Focus: Analyzing Takeda Pharmaceutical Co ADR (TAK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - Knox Daily
Brookline Bancorp, Inc. [BRKL] Records 50-Day SMA of $10.01 - Knox Daily
Crescent Energy Co. [CRGY] Records 200-Day SMA of $11.56 - Knox Daily
Tetra Tech, Inc. [TTEK] EVP, CFO makes an insider purchase of 36,830 shares worth 1.72 million. - Knox Daily
TAK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
大文字化:
|
ボリューム (24 時間):